Vascular Endothelial Growth Factor (VEGF165) Plus Basic Fibroblast Growth Factor (bFGF) Producing Cells induce a Mature and Stable Vascular Network—a Future Therapy for Ischemically Challenged Tissue

Spanholtz, Timo; Theodorou, Panagiotis; Holzbach, T.; Wutzler, Sebastian; Giunta, Riccardo E.; Machens, Hans‐Guenther

doi:10.1016/j.jss.2010.03.033

Cited by 39 publications

(34 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unexpectedly, there was no difference between PCL and PU scaffolds, or between seeded and unseeded scaffolds. A higher rate of blood vessel formation was expected in seeded constructs due to hypoxia-induced secretion of vascular endothelial growth factor by the seeded cells (Dolderer et al 2007;Hofer et al 2003;Kotch et al 1999;Pugh and Ratcliffe 2003;Spanholtz et al 2010;Tanaka et al 2003). Moreover, it was expected that highly interconnected PCL scaffolds would better facilitate blood vessel ingrowth than tortuous PU foams but no difference was observed here either.…”

Section: Discussionmentioning

confidence: 76%

Engineering of vascularized adipose constructs

et al. 2011

View full text Add to dashboard Cite

Adipose tissue engineering offers a promising alternative to the current surgical techniques for the treatment of soft tissue defects. It is a challenge to find the appropriate scaffold that not only represents a suitable environment for cells but also allows fabrication of customized tissue constructs, particularly in breast surgery. We investigated two different scaffolds for their potential use in adipose tissue regeneration. Sponge-like polyurethane scaffolds were prepared by mold casting with methylal as foaming agent, whereas polycaprolactone scaffolds with highly regular stacked-fiber architecture were fabricated with fused deposition modeling. Both scaffold types were seeded with human adipose tissue-derived precursor cells, cultured and implanted in nude mice using a femoral arteriovenous flow-through vessel loop for angiogenesis. In vitro, cells attached to both scaffolds and differentiated into adipocytes. In vivo, angiogenesis and adipose tissue formation were observed throughout both constructs after 2 and 4 weeks, with angiogenesis being comparable in seeded and unseeded constructs. Fibrous tissue formation and adipogenesis were more pronounced on polyurethane foam scaffolds than on polycaprolactone prototyped scaffolds. In conclusion, both scaffold designs can be effectively used for adipose tissue engineering.

show abstract

Section: Discussionmentioning

confidence: 76%

Engineering of vascularized adipose constructs

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Increasing evidence indicates that angiogenesis induced by vascular endothelial growth factor (VEGF) during the proliferative phase may contribute to wound healing and tissue repair [8,[10][11][12][13][14][15][16][17]. VEGF is widely released by many types of cells including platelets, endothelial cells, fibroblasts and macrophages [8,12,[18][19][20].…”

Section: Introductionmentioning

confidence: 99%

The role of vascular endothelial growth factor in fractional laser resurfacing with the carbon dioxide laser

Jiang

Zhou

et al. 2011

Lasers Med Sci

View full text Add to dashboard Cite

The aim of this study was to analyze the role of vascular endothelial growth factor (VEGF) in mechanisms of cutaneous remodeling induced by fractional CO(2) laser treatment. The dorsal skin of Kunming mice was exposed to a single-pass fractional CO(2) laser treatment. Biopsies were taken 1 h, and 1, 3, 7, 14, 28 and 56 days after treatment. Skin samples VEGF expression was evaluated by immunohistochemistry and ELISA, fibroblasts by hematoxylin-eosin staining, and types I and III collagen by ELISA. Staining for VEGF was found in many types of cell including fibroblasts. The amount of VEGF in the skin of laser-treated areas had increased significantly compared to that in the control areas on days 1 and 3 (P < 0.05, P < 0.01, respectively), then decreased by day 7 after treatment and returned to the baseline level. The number of fibroblasts in the skin of the laser-treated areas had increased significantly compared to that in control areas on days 3, 7, 14, 28 and 56 after irradiation (P < 0.05, P < 0.01, P < 0.01, P < 0.01, P < 0.01, respectively). The amount of type I collagen was significantly higher in the skin of the laser-treated areas compared to that in control areas from day 28 to day 56 (P < 0.05, respectively), and type III collagen was significantly higher from day 3 to day 56 (P < 0.05, P < 0.05, P < 0.05, P < 0.05, P < 0.01, respectively). There was a positive correlation between the level of VEGF and fibroblast proliferation early stage after laser treatment (r = 0.853, P < 0.01), but there was no correlation after the first week (r = -0.124, P > 0.05). The amounts of type I and III collagen showed no significant correlations with the expression of VEGF in the late stages after laser treatment (r = 0.417, P > 0.05 and r = 0.340, P > 0.05, respectively). The results suggest that VEGF might be mainly involved in the early stages of wound healing, including the stages of acute inflammation, fibroblast proliferation and vessel formation induced by fractional CO(2) laser resurfacing.

show abstract

“…Eicacy improvement in gene therapy can be achieved by combined approaches basing on the point that angiogenesis is a dynamic process controlled by numerous cytokines, each playing its party in initiation/cessation of diferent stages. This puts the basis for combined gene therapy to treat ischemia with higher eicacy and it has been supported by experimental indings using VEGF165 combined with another pro-angiogenic growth factor: bFGF [71], PDGF [72], angiopoietin-1 [73], or Stromal cell-derived factor-1α (SDF-1α) [74]. Our previous experience in mouse hind limb ischemia model showed that combination of VEGF165 and uPA [75] or HGF [76] induced angiogenic response more efectively than each factor alone or allowed to reduce pDNA dose for combined delivery [75].…”

Section: Gene Therapy For Angiogenesismentioning

confidence: 84%

Therapeutic Angiogenesis: Foundations and Practical Application

Макаревич¹,

Parfyonova²

2017

Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy

View full text Add to dashboard Cite

Angiogenesis as therapeutic target has emerged since early works by Judah Folkman, yet his "holy grail" was inhibiting vascular growth to block tumor nutrition. However, in modern biomedicine, "therapeutic angiogenesis" became a large ield focusing on stimulation of blood vessel growth for ischemia relief to reduce its detrimental efects in the tissues. In this review, we introduce basic principles of tissue vascularization in response to ischemia exploited in this ield. An overview of recent status in therapeutic angiogenesis is given with introduction to emerging technologies, including gene therapy, genetic modiication of cells ex vivo and tissue engineering.

show abstract

Vascular Endothelial Growth Factor (VEGF165) Plus Basic Fibroblast Growth Factor (bFGF) Producing Cells induce a Mature and Stable Vascular Network—a Future Therapy for Ischemically Challenged Tissue

Cited by 39 publications

References 27 publications

Engineering of vascularized adipose constructs

Engineering of vascularized adipose constructs

The role of vascular endothelial growth factor in fractional laser resurfacing with the carbon dioxide laser

Therapeutic Angiogenesis: Foundations and Practical Application

Contact Info

Product

Resources

About